Genfit Reports Positive Results In Phase II Trial For GFT505
Published: 26-Nov-2009
GFT505 was well tolerated and presented a good safety of use
Genfit has reported positive results in Phase II trial with its most advanced drug candidate, GFT505, in prediabetic patients with atherogenic dyslipidemia and abdominal obesity (study GFT505-2083).
The results of the clinical trial showed that GFT505 was well tolerated at the dose of 80mg/day and presented a good safety of use. No specific adverse event was observed in the GFT505 treated group relative to the placebo treated group.
In the study, all primary objectives were reached, claims the company. Relative to the placebo group, therapeutic efficacy of GFT505 was demonstrated with a statistically 21% reduction of plasma triglycerides and a 9% increase in good cholesterol (HDL-C) level.
In addition, GFT505 has revealed a lack of effect on a known cardiovasuclar risk factor, homocysteine (5% vs 40 to 50% reported with fenofibrate) and on a marker of renal dysfunction, creatinine (non significant vs 10 to 15% reported with fenofibrate). It also showed positive effects on multiple secondary evaluation criteria related to lipid metabolism and inflammation, and reduced acute phase inflammation markers such as fibrinogen and haptoglobin.
Jean-François Mouney, CEO of Genfit, said: "We are highly satisfied with these results which fulfill all our expectations. The safety of use as well as efficacy results on the primary end points of the study confirm that GFT505 has the potential of becoming a top drug for the medical care of various patient populations in prediabetic states.
“About 50% of these patients will evolve towards overt type II diabetes over five years. Thus, with the data already obtained, we are very confident in our capacity to find an industrial partner to pursue the clinical development of GFT505 and ensure its commercialisation. We are in close discussions with three international pharmaceutical groups and are initiating a due diligence with one of them."
Network Sites

Suppliers To This Sector
Browse A-Z
World Courier
Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...
Toxikon Europe
CRO Providing Preclinical Safety Studies for the Life Science Community ...
Thomson Reuters
The World's Leading Source of Life Sciences Intelligent Information ...
Synevo Central Lab
Clinical Laboratories ...
Swiss BioAnalytics
Quantitative and Qualitative LC/MS Services for Preclinical and Clinical Trials ...
Sparta Systems Europe
The Leader in Enterprise Quality Management Solutions ...
White Papers
Browse A-Z
CaseBase Management
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
SafetyBase Interchange
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
ClinicalBase Trial
BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...
Reliable Prediction of White Plasma Levels
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Kinetics and Metabolism
Our kinetics & metabolism experts can help you select and further develop your candidate d ...
Drug Safety Evaluation
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully